81_FR_2884 81 FR 2873 - Arthritis Advisory Committee; Notice of Meeting

81 FR 2873 - Arthritis Advisory Committee; Notice of Meeting

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration

Federal Register Volume 81, Issue 11 (January 19, 2016)

Page Range2873-2873
FR Document2016-00823

Federal Register, Volume 81 Issue 11 (Tuesday, January 19, 2016) 
[Federal Register Volume 81, Number 11 (Tuesday, January 19, 2016)]
[Notices]
[Page 2873]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2016-00823]



[[Page 2873]]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2016-N-0001]


Arthritis Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

    This notice announces a forthcoming meeting of a public advisory 
committee of the Food and Drug Administration (FDA). The meeting will 
be open to the public.
    Name of Committee: Arthritis Advisory Committee.
    General Function of the Committee: To provide advice and 
recommendations to the Agency on FDA's regulatory issues.
    Date and Time: The meeting will be held on February 9, 2016, from 
7:30 a.m. to 5 p.m.
    Location: FDA White Oak Campus, 10903 New Hampshire Ave., Bldg. 31 
Conference Center, the Great Room (Rm. 1503), Silver Spring, MD 20993-
0002. Answers to commonly asked questions including information 
regarding special accommodations due to a disability, visitor parking, 
and transportation may be accessed at: http://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm408555.htm.
    Contact Person: Stephanie L. Begansky, Center for Drug Evaluation 
and Research, Food and Drug Administration, 10903 New Hampshire Ave., 
Bldg. 31, Rm. 2417, Silver Spring, MD 20993-0002, 301-796-9001, FAX: 
301-847-8533, [email protected], or FDA Advisory Committee Information 
Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area). A 
notice in the Federal Register about last minute modifications that 
impact a previously announced advisory committee meeting cannot always 
be published quickly enough to provide timely notice. Therefore, you 
should always check the Agency's Web site at http://www.fda.gov/AdvisoryCommittees/default.htm and scroll down to the appropriate 
advisory committee meeting link, or call the advisory committee 
information line to learn about possible modifications before coming to 
the meeting.
    Agenda: The committee will discuss biologics license application 
(BLA) 125544, for CT-P13, a proposed biosimilar to Janssen Biotech 
Inc.'s REMICADE (infliximab), submitted by Celltrion, Inc. The proposed 
indications (uses) for this product are: (1) Reducing signs and 
symptoms and inducing and maintaining clinical remission in adult 
patients with moderately to severely active Crohn's disease who have 
had an inadequate response to conventional therapy; (2) reducing the 
number of draining enterocutaneous and rectovaginal fistulas and 
maintaining fistula closure in adult patients with fistulizing Crohn's 
disease; (3) reducing signs and symptoms and inducing and maintaining 
clinical remission in pediatric patients 6 years of age and older with 
moderately to severely active Crohn's disease who have had an 
inadequate response to conventional therapy; (4) reducing signs and 
symptoms, inducing and maintaining clinical remission and mucosal 
healing, and eliminating corticosteroid use in adult patients with 
moderately to severely active ulcerative colitis who have had an 
inadequate response to conventional therapy; (5) reducing signs and 
symptoms and inducing and maintaining clinical remission in pediatric 
patients 6 years of age and older with moderately to severely active 
ulcerative colitis who have had an inadequate response to conventional 
therapy; \1\ (6) in combination with methotrexate, reducing signs and 
symptoms, inhibiting the progression of structural damage, and 
improving physical function in patients with moderately to severely 
active rheumatoid arthritis; (7) reducing signs and symptoms in 
patients with active ankylosing spondylitis; (8) reducing signs and 
symptoms of active arthritis, inhibiting the progression of structural 
damage, and improving physical function in patients with psoriatic 
arthritis; and (9) treatment of adult patients with chronic severe 
(i.e., extensive and/or disabling) plaque psoriasis who are candidates 
for systemic therapy and when other systemic therapies are medically 
less appropriate.
---------------------------------------------------------------------------

    \1\ This indication is protected by orphan drug exclusivity 
expiring on September 23, 2018. See the Orphan Drug Designations and 
Approvals database at http://www.accessdata.fda.gov/scripts/opdlisting/oopd/index.cfm.
---------------------------------------------------------------------------

    FDA intends to make background material available to the public no 
later than 2 business days before the meeting. If FDA is unable to post 
the background material on its Web site prior to the meeting, the 
background material will be made publicly available at the location of 
the advisory committee meeting, and the background material will be 
posted on FDA's Web site after the meeting. Background material is 
available at http://www.fda.gov/AdvisoryCommittees/Calendar/default.htm. Scroll down to the appropriate advisory committee meeting 
link.
    Procedure: Interested persons may present data, information, or 
views, orally or in writing, on issues pending before the committee. 
Written submissions may be made to the contact person on or before 
January 26, 2016. Oral presentations from the public will be scheduled 
between approximately 1:30 p.m. and 3 p.m. Those individuals interested 
in making formal oral presentations should notify the contact person 
and submit a brief statement of the general nature of the evidence or 
arguments they wish to present, the names and addresses of proposed 
participants, and an indication of the approximate time requested to 
make their presentation on or before January 25, 2016. Time allotted 
for each presentation may be limited. If the number of registrants 
requesting to speak is greater than can be reasonably accommodated 
during the scheduled open public hearing session, FDA may conduct a 
lottery to determine the speakers for the scheduled open public hearing 
session. The contact person will notify interested persons regarding 
their request to speak by January 15, 2016.
    Persons attending FDA's advisory committee meetings are advised 
that the Agency is not responsible for providing access to electrical 
outlets.
    FDA welcomes the attendance of the public at its advisory committee 
meetings and will make every effort to accommodate persons with 
disabilities. If you require accommodations due to a disability, please 
contact Stephanie L. Begansky at least 7 days in advance of the 
meeting.
    FDA is committed to the orderly conduct of its advisory committee 
meetings. Please visit our Web site at http://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm for procedures 
on public conduct during advisory committee meetings.
    Notice of this meeting is given under the Federal Advisory 
Committee Act (5 U.S.C. app. 2).

    Dated: January 11, 2016.
Jill Hartzler Warner,
Associate Commissioner for Special Medical Programs.
[FR Doc. 2016-00823 Filed 1-15-16; 8:45 am]
 BILLING CODE 4164-01-P

Federal Register / Vol. 81, No. 11 / Tuesday, January 19, 2016 / Notices 2873 DEPARTMENT OF HEALTH AND (uses) for this product are: (1) Reducing AdvisoryCommittees/Calendar/ HUMAN SERVICES signs and symptoms and inducing and default.htm. Scroll down to the maintaining clinical remission in adult appropriate advisory committee meeting Food and Drug Administration patients with moderately to severely link. [Docket No. FDA–2016–N–0001] active Crohn’s disease who have had an Procedure: Interested persons may inadequate response to conventional present data, information, or views, Arthritis Advisory Committee; Notice therapy; (2) reducing the number of orally or in writing, on issues pending of Meeting draining enterocutaneous and rectovaginal fistulas and maintaining before the committee. Written AGENCY: Food and Drug Administration, fistula closure in adult patients with submissions may be made to the contact HHS. fistulizing Crohn’s disease; (3) reducing person on or before January 26, 2016. ACTION: Notice. signs and symptoms and inducing and Oral presentations from the public will maintaining clinical remission in be scheduled between approximately This notice announces a forthcoming 1:30 p.m. and 3 p.m. Those individuals pediatric patients 6 years of age and meeting of a public advisory committee interested in making formal oral older with moderately to severely active of the Food and Drug Administration presentations should notify the contact Crohn’s disease who have had an (FDA). The meeting will be open to the person and submit a brief statement of inadequate response to conventional public. the general nature of the evidence or therapy; (4) reducing signs and Name of Committee: Arthritis symptoms, inducing and maintaining arguments they wish to present, the Advisory Committee. General Function of the Committee: clinical remission and mucosal healing, names and addresses of proposed To provide advice and and eliminating corticosteroid use in participants, and an indication of the recommendations to the Agency on adult patients with moderately to approximate time requested to make FDA’s regulatory issues. severely active ulcerative colitis who their presentation on or before January Date and Time: The meeting will be have had an inadequate response to 25, 2016. Time allotted for each held on February 9, 2016, from 7:30 a.m. conventional therapy; (5) reducing signs presentation may be limited. If the to 5 p.m. and symptoms and inducing and number of registrants requesting to Location: FDA White Oak Campus, maintaining clinical remission in speak is greater than can be reasonably 10903 New Hampshire Ave., Bldg. 31 pediatric patients 6 years of age and accommodated during the scheduled Conference Center, the Great Room (Rm. older with moderately to severely active open public hearing session, FDA may 1503), Silver Spring, MD 20993–0002. ulcerative colitis who have had an conduct a lottery to determine the Answers to commonly asked questions inadequate response to conventional speakers for the scheduled open public including information regarding special therapy; 1 (6) in combination with hearing session. The contact person will accommodations due to a disability, methotrexate, reducing signs and notify interested persons regarding their visitor parking, and transportation may symptoms, inhibiting the progression of request to speak by January 15, 2016. be accessed at: http://www.fda.gov/ structural damage, and improving AdvisoryCommittees/ physical function in patients with Persons attending FDA’s advisory AboutAdvisoryCommittees/ moderately to severely active committee meetings are advised that the ucm408555.htm. rheumatoid arthritis; (7) reducing signs Agency is not responsible for providing Contact Person: Stephanie L. and symptoms in patients with active access to electrical outlets. Begansky, Center for Drug Evaluation ankylosing spondylitis; (8) reducing FDA welcomes the attendance of the and Research, Food and Drug signs and symptoms of active arthritis, public at its advisory committee Administration, 10903 New Hampshire inhibiting the progression of structural meetings and will make every effort to Ave., Bldg. 31, Rm. 2417, Silver Spring, damage, and improving physical accommodate persons with disabilities. MD 20993–0002, 301–796–9001, FAX: function in patients with psoriatic If you require accommodations due to a 301–847–8533, AAC@fda.hhs.gov, or arthritis; and (9) treatment of adult disability, please contact Stephanie L. FDA Advisory Committee Information patients with chronic severe (i.e., extensive and/or disabling) plaque Begansky at least 7 days in advance of Line, 1–800–741–8138 (301–443–0572 the meeting. in the Washington, DC area). A notice in psoriasis who are candidates for the Federal Register about last minute systemic therapy and when other FDA is committed to the orderly modifications that impact a previously systemic therapies are medically less conduct of its advisory committee announced advisory committee meeting appropriate. meetings. Please visit our Web site at cannot always be published quickly FDA intends to make background http://www.fda.gov/ enough to provide timely notice. material available to the public no later AdvisoryCommittees/ Therefore, you should always check the than 2 business days before the meeting. AboutAdvisoryCommittees/ Agency’s Web site at http:// If FDA is unable to post the background ucm111462.htm for procedures on www.fda.gov/AdvisoryCommittees/ material on its Web site prior to the public conduct during advisory default.htm and scroll down to the meeting, the background material will committee meetings. appropriate advisory committee meeting be made publicly available at the location of the advisory committee Notice of this meeting is given under link, or call the advisory committee the Federal Advisory Committee Act (5 information line to learn about possible meeting, and the background material asabaliauskas on DSK5VPTVN1PROD with NOTICES will be posted on FDA’s Web site after U.S.C. app. 2). modifications before coming to the meeting. the meeting. Background material is Dated: January 11, 2016. Agenda: The committee will discuss available at http://www.fda.gov/ Jill Hartzler Warner, biologics license application (BLA) Associate Commissioner for Special Medical 1 This indication is protected by orphan drug 125544, for CT–P13, a proposed Programs. exclusivity expiring on September 23, 2018. See the biosimilar to Janssen Biotech Inc.’s Orphan Drug Designations and Approvals database [FR Doc. 2016–00823 Filed 1–15–16; 8:45 am] REMICADE (infliximab), submitted by at http://www.accessdata.fda.gov/scripts/ BILLING CODE 4164–01–P Celltrion, Inc. The proposed indications opdlisting/oopd/index.cfm. VerDate Sep<11>2014 17:50 Jan 15, 2016 Jkt 238001 PO 00000 Frm 00037 Fmt 4703 Sfmt 9990 E:\FR\FM\19JAN1.SGM 19JAN1


Document Created: 2016-01-16 01:10:35
Document Modified: 2016-01-16 01:10:35
CategoryRegulatory Information
CollectionFederal Register
sudoc ClassAE 2.7:
GS 4.107:
AE 2.106:
PublisherOffice of the Federal Register, National Archives and Records Administration
SectionNotices
ActionNotice.
FR Citation81 FR 2873 
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR